Sectors

KYNB
Kyntra Bio, Inc.
7.12
1 x 7.13
2 x 7.20
bid
ask
-
0.18
2.46%
11:01 AM
timesize
Ytd-25.05%
1y-25.05%
7.13
day range
7.30
6.32
52 week range
12.60
Open7.30Prev Close7.30Low7.13High7.30Mkt Cap29.55M
Vol3.26KAvg Vol18.47KEPS-12.34P/E-0.59Forward P/EN/A
Beta0.96Short RatioN/AInst. OwnN/ADividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg7.05200-d Avg8.141yr Est0.00

KYNB News

Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)
defenseworld.net
Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)

Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations Fo

Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, S

benzinga.com
Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform ra

benzinga.com
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardl

The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
globenewswire.com
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ri

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additiona

benzinga.com
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) w

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
seekingalpha.com
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estim

benzinga.com
Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent de

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial r

Earnings Scheduled For May 11, 2026
benzinga.com
Earnings Scheduled For May 11, 2026

Kyntra Bio to Report First Quarter 2026 Financial Results
globenewswire.com
Kyntra Bio to Report First Quarter 2026 Financial Results

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
zacks.com
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the

Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
seekingalpha.com
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

benzinga.com
Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst conse

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targe

Earnings Scheduled For March 16, 2026
benzinga.com
Earnings Scheduled For March 16, 2026

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
zacks.com
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings b

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasd

What's Going On With Kyntra Bio Stock Tuesday?
benzinga.com
What's Going On With Kyntra Bio Stock Tuesday?

Kyntra Bio Inc. (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday's premarket session

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
globenewswire.com
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Co

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasda

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
globenewswire.com
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it i

FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
seekingalpha.com
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Tha

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimat

FibroGen to Report Third Quarter 2025 Financial Results
globenewswire.com
FibroGen to Report Third Quarter 2025 Financial Results

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third q

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
globenewswire.com
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Met

SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
globenewswire.com
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that